Introduction to May 08 2026 This Week In Cardiology
Exploring May 08 2026 This Week In Cardiology reveals several interesting facts. Listener feedback from the DanGer Shock investigators, complete vs staged revascularization, polygenic risk scores, and quality ...
May 08 2026 This Week In Cardiology Comprehensive Overview
Time to quadruple therapy, the disappointing AVANT GUARD trial, PFA risks, the TREAT-PVC trial, and NSTEMI care in the frail ... A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in Listener feedback, transcatheter tricuspid valve replacement, a new metabolic disease called CKM, the ARISE-FLUIDS Trial, the ...
EVOLUT Low Risk data, a provocative meta-analysis, DNR orders, targeted hypothermia, good news in HFpEF evidence, and ...
Summary & Highlights for May 08 2026 This Week In Cardiology
- PCSK9 inhibitors in high-risk diabetes without ASCVD, the CAAN-AF trial, conduction system pacing vs biventricular pacing, PFA ...
- John Mandrola offers an ACC recap of 5 big trials—Hi-PEITHO, PROTAVI, ORBITA-CTO, CHIPS-BCIS3 and CHAMPION AF This ...
- Three more digoxin trials, yet another GLP-1 drug on the horizon, vagal nerve stimulation, trial inside baseball, and more on lipid ...
- Three imaging-guided PCI trials (two with surprising results), LDL targets, an oral PCSK9 inhibitor, and another beta-blocker ...
- Listener feedback on valvular heart disease, statins and frailty, left atrial posterior wall ablation fails again, interpreting medical ...
Stay tuned for more updates related to May 08 2026 This Week In Cardiology.
